Valerius is developing specialty biosimilars for global markets according to the strict directions from US and EU regulatory bodies.

Our first biosimilar candidates are currently in early pre-clinical development and include monoclonal antibodies, enzymes and fusion proteins covering different therapeutic areas such as oncology, inflammation, ophthalmology and respiratory.